vs

Side-by-side financial comparison of ACM Research, Inc. (ACMR) and Harmony Biosciences Holdings, Inc. (HRMY). Click either name above to swap in a different company.

Harmony Biosciences Holdings, Inc. is the larger business by last-quarter revenue ($243.8M vs $231.3M, roughly 1.1× ACM Research, Inc.). Harmony Biosciences Holdings, Inc. runs the higher net margin — 9.2% vs 7.5%, a 1.7% gap on every dollar of revenue. On growth, ACM Research, Inc. posted the faster year-over-year revenue change (34.2% vs 21.1%). Over the past eight quarters, Harmony Biosciences Holdings, Inc.'s revenue compounded faster (25.6% CAGR vs 6.9%).

ACM Research, Inc. is a leading global supplier of advanced processing equipment for the semiconductor manufacturing industry. It designs, develops and commercializes high-performance wet processing systems including wafer cleaning, electroplating and etching tools, which support production of advanced logic, memory and power semiconductor chips, serving chip manufacturers across Asia, North America and Europe.

Harmony Biosciences Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare neurological and central nervous system disorders. Its primary market is the United States, with its core product serving patients living with narcolepsy and other sleep-related CNS conditions across adult and pediatric segments.

ACMR vs HRMY — Head-to-Head

Bigger by revenue
HRMY
HRMY
1.1× larger
HRMY
$243.8M
$231.3M
ACMR
Growing faster (revenue YoY)
ACMR
ACMR
+13.1% gap
ACMR
34.2%
21.1%
HRMY
Higher net margin
HRMY
HRMY
1.7% more per $
HRMY
9.2%
7.5%
ACMR
Faster 2-yr revenue CAGR
HRMY
HRMY
Annualised
HRMY
25.6%
6.9%
ACMR

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ACMR
ACMR
HRMY
HRMY
Revenue
$231.3M
$243.8M
Net Profit
$17.3M
$22.5M
Gross Margin
46.4%
71.9%
Operating Margin
15.6%
15.8%
Net Margin
7.5%
9.2%
Revenue YoY
34.2%
21.1%
Net Profit YoY
-44.7%
-54.6%
EPS (diluted)
$0.24
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACMR
ACMR
HRMY
HRMY
Q1 26
$231.3M
Q4 25
$244.4M
$243.8M
Q3 25
$269.2M
$239.5M
Q2 25
$215.4M
$200.5M
Q1 25
$172.3M
$184.7M
Q4 24
$223.5M
$201.3M
Q3 24
$204.0M
$186.0M
Q2 24
$202.5M
$172.8M
Net Profit
ACMR
ACMR
HRMY
HRMY
Q1 26
$17.3M
Q4 25
$8.0M
$22.5M
Q3 25
$35.9M
$50.9M
Q2 25
$29.8M
$39.8M
Q1 25
$20.4M
$45.6M
Q4 24
$31.1M
$49.5M
Q3 24
$30.9M
$46.1M
Q2 24
$24.2M
$11.6M
Gross Margin
ACMR
ACMR
HRMY
HRMY
Q1 26
46.4%
Q4 25
40.9%
71.9%
Q3 25
42.0%
75.1%
Q2 25
48.5%
81.0%
Q1 25
47.9%
82.7%
Q4 24
49.6%
73.0%
Q3 24
51.4%
77.0%
Q2 24
47.8%
81.4%
Operating Margin
ACMR
ACMR
HRMY
HRMY
Q1 26
15.6%
Q4 25
9.4%
15.8%
Q3 25
10.7%
27.3%
Q2 25
14.7%
24.0%
Q1 25
15.0%
30.4%
Q4 24
19.7%
27.7%
Q3 24
21.7%
33.2%
Q2 24
18.6%
12.4%
Net Margin
ACMR
ACMR
HRMY
HRMY
Q1 26
7.5%
Q4 25
3.3%
9.2%
Q3 25
13.3%
21.2%
Q2 25
13.8%
19.8%
Q1 25
11.8%
24.7%
Q4 24
13.9%
24.6%
Q3 24
15.2%
24.8%
Q2 24
12.0%
6.7%
EPS (diluted)
ACMR
ACMR
HRMY
HRMY
Q1 26
$0.24
Q4 25
$0.11
$0.38
Q3 25
$0.52
$0.87
Q2 25
$0.44
$0.68
Q1 25
$0.30
$0.78
Q4 24
$0.47
$0.85
Q3 24
$0.45
$0.79
Q2 24
$0.35
$0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACMR
ACMR
HRMY
HRMY
Cash + ST InvestmentsLiquidity on hand
$872.3M
$775.3M
Total DebtLower is stronger
$314.8M
$163.7M
Stockholders' EquityBook value
$2.1B
$870.2M
Total Assets
$3.1B
$1.3B
Debt / EquityLower = less leverage
0.15×
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACMR
ACMR
HRMY
HRMY
Q1 26
$872.3M
Q4 25
$792.9M
$775.3M
Q3 25
$1.1B
$672.6M
Q2 25
$463.2M
$565.3M
Q1 25
$475.6M
$507.0M
Q4 24
$426.8M
$467.2M
Q3 24
$353.8M
$410.5M
Q2 24
$343.6M
$346.9M
Total Debt
ACMR
ACMR
HRMY
HRMY
Q1 26
$314.8M
Q4 25
$214.0M
$163.7M
Q3 25
$242.0M
$168.5M
Q2 25
$225.1M
$172.1M
Q1 25
$202.5M
$175.7M
Q4 24
$150.0M
$179.3M
Q3 24
$150.0M
$182.8M
Q2 24
$90.5M
$186.4M
Stockholders' Equity
ACMR
ACMR
HRMY
HRMY
Q1 26
$2.1B
Q4 25
$1.5B
$870.2M
Q3 25
$1.4B
$835.1M
Q2 25
$986.5M
$773.1M
Q1 25
$949.1M
$720.5M
Q4 24
$904.6M
$659.2M
Q3 24
$888.2M
$596.8M
Q2 24
$833.2M
$538.6M
Total Assets
ACMR
ACMR
HRMY
HRMY
Q1 26
$3.1B
Q4 25
$2.9B
$1.3B
Q3 25
$2.8B
$1.2B
Q2 25
$2.0B
$1.1B
Q1 25
$1.9B
$1.1B
Q4 24
$1.9B
$999.2M
Q3 24
$1.8B
$928.1M
Q2 24
$1.7B
$858.4M
Debt / Equity
ACMR
ACMR
HRMY
HRMY
Q1 26
0.15×
Q4 25
0.15×
0.19×
Q3 25
0.17×
0.20×
Q2 25
0.23×
0.22×
Q1 25
0.21×
0.24×
Q4 24
0.17×
0.27×
Q3 24
0.17×
0.31×
Q2 24
0.11×
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACMR
ACMR
HRMY
HRMY
Operating Cash FlowLast quarter
$126.2M
Free Cash FlowOCF − Capex
$126.0M
FCF MarginFCF / Revenue
51.7%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
5.61×
TTM Free Cash FlowTrailing 4 quarters
$347.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACMR
ACMR
HRMY
HRMY
Q1 26
Q4 25
$33.9M
$126.2M
Q3 25
$-4.6M
$108.7M
Q2 25
$-44.9M
$79.3M
Q1 25
$5.3M
$34.0M
Q4 24
$88.6M
$75.6M
Q3 24
$11.9M
$70.5M
Q2 24
$61.6M
$42.6M
Free Cash Flow
ACMR
ACMR
HRMY
HRMY
Q1 26
Q4 25
$20.1M
$126.0M
Q3 25
$-15.6M
$108.7M
Q2 25
$-59.6M
$79.3M
Q1 25
$-11.4M
$33.9M
Q4 24
$77.2M
$75.0M
Q3 24
$-20.6M
$70.5M
Q2 24
$48.5M
$42.0M
FCF Margin
ACMR
ACMR
HRMY
HRMY
Q1 26
Q4 25
8.2%
51.7%
Q3 25
-5.8%
45.4%
Q2 25
-27.7%
39.6%
Q1 25
-6.6%
18.3%
Q4 24
34.5%
37.3%
Q3 24
-10.1%
37.9%
Q2 24
24.0%
24.3%
Capex Intensity
ACMR
ACMR
HRMY
HRMY
Q1 26
Q4 25
5.6%
0.0%
Q3 25
4.1%
0.0%
Q2 25
6.8%
0.0%
Q1 25
9.7%
0.1%
Q4 24
5.1%
0.3%
Q3 24
16.0%
0.0%
Q2 24
6.5%
0.4%
Cash Conversion
ACMR
ACMR
HRMY
HRMY
Q1 26
Q4 25
4.21×
5.61×
Q3 25
-0.13×
2.14×
Q2 25
-1.51×
1.99×
Q1 25
0.26×
0.75×
Q4 24
2.85×
1.53×
Q3 24
0.39×
1.53×
Q2 24
2.54×
3.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons